<DOC>
	<DOC>NCT01336465</DOC>
	<brief_summary>This Phase II study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis.</brief_summary>
	<brief_title>Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Diagnosis of moderate to severe ulcerative colitis outpatient Disease duration at time of screening of &gt;/= 12 weeks Extensive colonic resection or subtotal or total colectomy Presence of an ileostomy or colostomy Moderate to severe anemia A history or evidence of colonic mucosal dysplasia Pregnant or lactating Significant uncontrolled comorbidity, such as neurological, cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal (GI) disorders Significant screening ECG abnormalities, including evidence of acute myocardial infarction, complete left bundle branch block, seconddegree heart block, or complete heart block Poorly controlled diabetes Impaired renal function Impaired hepatic function in the absence of a diagnosis of primary sclerosing cholangitis Positive tests for antibodies indicating active or prior infection with HIV or hepatitis B (HBV) or C (HCV) Positive screening test for latent mycobacterium tuberculosis (TB) infection Demyelinating disease Received any investigational treatment within 12 weeks prior to initiation of study treatment Previous exposure to rhuMAb Beta7</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>